BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $60.00 Price Target at Royal Bank Of Canada

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective reduced by investment analysts at Royal Bank Of Canada from $62.00 to $60.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada‘s target price suggests a potential upside of 9.00% from the stock’s current price.

A number of other equities research analysts also recently issued reports on BMRN. JPMorgan Chase & Co. boosted their price target on BioMarin Pharmaceutical from $86.00 to $87.00 and gave the company an “overweight” rating in a research note on Tuesday, October 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $86.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 20th. Morgan Stanley dropped their price objective on shares of BioMarin Pharmaceutical from $124.00 to $122.00 and set an “overweight” rating on the stock in a report on Wednesday, October 21st. HC Wainwright restated a “neutral” rating and set a $60.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, September 10th. Finally, Citigroup upped their target price on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $88.09.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ BMRN traded down $2.39 during midday trading on Tuesday, hitting $55.05. 411,376 shares of the stock traded hands, compared to its average volume of 2,103,768. The firm has a 50-day moving average of $60.43 and a two-hundred day moving average of $58.46. The firm has a market capitalization of $10.66 billion, a P/E ratio of 149.34, a PEG ratio of 0.61 and a beta of 0.22. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.31. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. BioMarin Pharmaceutical’s revenue was up 32.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 earnings per share. On average, equities analysts forecast that BioMarin Pharmaceutical will post 2.59 EPS for the current fiscal year.

Institutional Trading of BioMarin Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the company. Primecap Management Co. CA purchased a new stake in shares of BioMarin Pharmaceutical in the second quarter worth about $811,962,000. Dimensional Fund Advisors LP grew its holdings in BioMarin Pharmaceutical by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company’s stock valued at $214,804,000 after buying an additional 481,176 shares in the last quarter. First Trust Advisors LP grew its holdings in BioMarin Pharmaceutical by 43.3% during the 1st quarter. First Trust Advisors LP now owns 1,672,491 shares of the biotechnology company’s stock valued at $94,479,000 after buying an additional 505,692 shares in the last quarter. Caisse de depot et placement du Quebec bought a new stake in BioMarin Pharmaceutical in the 2nd quarter worth approximately $70,749,000. Finally, Bank of New York Mellon Corp bought a new stake in BioMarin Pharmaceutical in the 2nd quarter worth approximately $66,107,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and broadly in line with estimates. Growth was led by a 44% increase in metabolic-condition revenue and a 12% increase in skeletal-condition revenue. Adjusted EPS of $0.23 substantially exceeded the consensus estimate for a loss of approximately $0.08. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company expanded its pipeline with a new investigational Fabry-disease asset and reported a May 30, 2027, FDA action date for VOXZOGO in hypochondroplasia. These developments support BioMarin’s longer-term growth prospects. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Citi reiterated a Buy rating, arguing that the timing-related setback does not undermine BioMarin’s long-term potential and citing approximately 32% upside. Other commentary described the stock as potentially undervalued following the Fabry deal and mixed guidance. BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential
• Negative Sentiment: BioMarin lowered fiscal 2026 EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and set revenue guidance at $3.8–$3.9 billion versus a $3.9 billion consensus. The lower outlook may outweigh the quarterly earnings beat in the near term. BMRN Q3 Deep Dive
• Neutral Sentiment: Management characterized the outlook issue as primarily related to order timing, while acquired IPR&D charges also affected earnings expectations. Investors will likely focus on whether demand timing normalizes and whether the expanded pipeline generates future growth.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.